Systemic Anti-Cancer Therapy Regimen Library
Pethema LPA2005 [over 70 years] [high risk] - Consolidation 1 (LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [over 70 years] [high risk])
Treatment Overview
Starts after count recovery from Induction, with neutrophils greater than 1.5 x 109/L and platelets greater than 100 x 109/L.
Cycle 1 - 28 days
tretinoin: Teratogenic—Ensure pregnant women are not exposed to tretinoin. Consult prescribing information.
Cycle details
Cycle 1 - 28 days
| Medication | Dose | Route | Days | Max Duration |
|---|---|---|---|---|
| tretinoin * | 45 mg/m² Daily in divided doses | oral administration | 1 to 15 | |
| IDArubicin * | 7 mg/m² Once daily | intravenous | 1 to 4 | 15 minutes |
tretinoin: Teratogenic—Ensure pregnant women are not exposed to tretinoin. Consult prescribing information.
Full details
Cycle 1 - 28 days
Day: 1
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| tretinoin * | 45 mg/m² Daily in divided doses | oral administration |
Instructions:
Additional details:
Daily in TWO divided doses.
|
|
| IDArubicin * | 7 mg/m² Once daily | intravenous | 15 minutes |
Instructions:
Warning vesicant—ensure vein is patent prior to administration, administer vesicant as per institutional policy and monitor for signs of extravasation throughout administration. |
Day: 2
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| tretinoin * | 45 mg/m² Daily in divided doses | oral administration |
Instructions:
Additional details:
Daily in TWO divided doses.
|
|
| IDArubicin * | 7 mg/m² Once daily | intravenous | 15 minutes |
Instructions:
Warning vesicant—ensure vein is patent prior to administration, administer vesicant as per institutional policy and monitor for signs of extravasation throughout administration. |
Day: 3
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| tretinoin * | 45 mg/m² Daily in divided doses | oral administration |
Instructions:
Additional details:
Daily in TWO divided doses.
|
|
| IDArubicin * | 7 mg/m² Once daily | intravenous | 15 minutes |
Instructions:
Warning vesicant—ensure vein is patent prior to administration, administer vesicant as per institutional policy and monitor for signs of extravasation throughout administration. |
Day: 4
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| tretinoin * | 45 mg/m² Daily in divided doses | oral administration |
Instructions:
Additional details:
Daily in TWO divided doses.
|
|
| IDArubicin * | 7 mg/m² Once daily | intravenous | 15 minutes |
Instructions:
Warning vesicant—ensure vein is patent prior to administration, administer vesicant as per institutional policy and monitor for signs of extravasation throughout administration. |
Day: 5
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| tretinoin * | 45 mg/m² Daily in divided doses | oral administration |
Instructions:
Additional details:
Daily in TWO divided doses.
|
Day: 6
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| tretinoin * | 45 mg/m² Daily in divided doses | oral administration |
Instructions:
Additional details:
Daily in TWO divided doses.
|
Day: 7
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| tretinoin * | 45 mg/m² Daily in divided doses | oral administration |
Instructions:
Additional details:
Daily in TWO divided doses.
|
Day: 8
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| tretinoin * | 45 mg/m² Daily in divided doses | oral administration |
Instructions:
Additional details:
Daily in TWO divided doses.
|
Day: 9
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| tretinoin * | 45 mg/m² Daily in divided doses | oral administration |
Instructions:
Additional details:
Daily in TWO divided doses.
|
Day: 10
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| tretinoin * | 45 mg/m² Daily in divided doses | oral administration |
Instructions:
Additional details:
Daily in TWO divided doses.
|
Day: 11
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| tretinoin * | 45 mg/m² Daily in divided doses | oral administration |
Instructions:
Additional details:
Daily in TWO divided doses.
|
Day: 12
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| tretinoin * | 45 mg/m² Daily in divided doses | oral administration |
Instructions:
Additional details:
Daily in TWO divided doses.
|
Day: 13
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| tretinoin * | 45 mg/m² Daily in divided doses | oral administration |
Instructions:
Additional details:
Daily in TWO divided doses.
|
Day: 14
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| tretinoin * | 45 mg/m² Daily in divided doses | oral administration |
Instructions:
Additional details:
Daily in TWO divided doses.
|
Day: 15
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| tretinoin * | 45 mg/m² Daily in divided doses | oral administration |
Instructions:
Additional details:
Daily in TWO divided doses.
|
Additional details
Section 1: Teratogenic effects
Ensure pregnant women are not exposed to tretinoin. Consult prescribing information.
Supportive Care Factors
| Factor | Value |
|---|---|
| Antifungal prophylaxis: | Routine antifungal prophylaxis may be considered |
| Antiviral prophylaxis for herpes virus: | Routine antiviral prophylaxis recommended |
| Emetogenicity: | Variable |
Antiviral prophylaxis for hepatitis B virus: Guidance is limited to high-risk anti-cancer medicines. Clinicians will need to assess individual patient risk for other anti-cancer medicines.
Emetogenicity:
- MEDIUM days 1 to 4;
- MINIMAL to LOW (oral) days 5 to 15.
References
Pharmaco (NZ) Ltd Vesanoid® New Zealand data sheet 21 April 2022 https://www.medsafe.govt.nz/profs/datasheet/v/Vesanoidcap.pdf (accessed 15 July 2022).
* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.
s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.